FDA Approved: PADCEV EJFV — Supplemental Application (SEAGEN INC.)

View source ↗

Summary

FDA notes a supplemental application for PADCEV EJFV (enfortumab vedotin) from Seagen, likely seeking labeling changes or expansion of the approved indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• PADCEV EJFV (enfortumab vedotin)

Snippet

SUPPL AP for PADCEV EJFV (ENFORTUMAB VEDOTIN)